TRX-914

TRX-914 is an investigational therapeutic being developed by TRX Biosciences for the treatment of depression. The drug utilizes TRX Biosciences' proprietary delivery technology, which is designed to achieve targeted delivery to the brain. This approach aims to enhance the transport of the active therapeutic agent across the blood-brain barrier or specifically to neural tissues to improve efficacy and potentially reduce systemic side effects. While the specific molecular target and the identity of the underlying active pharmaceutical ingredient have not been publicly disclosed, the program is part of TRX Biosciences' wholly owned pipeline focusing on optimized delivery of established or novel compounds.